Gijs Hubben
University of Groningen
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Gijs Hubben.
PLOS ONE | 2011
Gijs Hubben; Martin C. J. Bootsma; Michiel Luteijn; Diarmuid M. Glynn; David Bishai; Marc J. M. Bonten; Maarten Postma
Background Screening at hospital admission for carriage of methicillin-resistant Staphylococcus aureus (MRSA) has been proposed as a strategy to reduce nosocomial infections. The objective of this study was to determine the long-term costs and health benefits of selective and universal screening for MRSA at hospital admission, using both PCR-based and chromogenic media-based tests in various settings. Methodology/Principal Findings A simulation model of MRSA transmission was used to determine costs and effects over 15 years from a US healthcare perspective. We compared admission screening together with isolation of identified carriers against a baseline policy without screening or isolation. Strategies included selective screening of high risk patients or universal admission screening, with PCR-based or chromogenic media-based tests, in medium (5%) or high nosocomial prevalence (15%) settings. The costs of screening and isolation per averted MRSA infection were lowest using selective chromogenic-based screening in high and medium prevalence settings, at
Clinical Microbiology and Infection | 2011
J. M. Luteijn; Gijs Hubben; Petros Pechlivanoglou; Marc J. M. Bonten; Maarten Postma
4,100 and
Transfusion | 2009
Marinus van Hulst; Gijs Hubben; Kwamena W. Sagoe; Charupon Promwong; Parichart Permpikul; Ladda Fongsatitkul; Diarmuid M. Glynn; Cees Th. Smit Sibinga; Maarten Postma
10,300, respectively. Replacing the chromogenic-based test with a PCR-based test costs
Aids Care-psychological and Socio-medical Aspects of Aids\/hiv | 2008
Gijs Hubben; David Bishai; Petros Pechlivanoglou; Anna Maria Cattelan; R. Grisetti; Chiara Facchin; F. A. Compostella; Jasper M. Bos; Maarten Postma; A. Tramarin
13,000 and
Archive | 2008
Gijs Hubben; David Bishai; Petros Pechlivanoglou; Anna Maria Cattelan; Roberta Grisetti; Chiara Facchin; F.A. Compostella; Jasper M. Bos; Maarten Postma; A. Tramarin
36,200 per additional infection averted, and subsequent extension to universal screening with PCR would cost
Cost Effectiveness and Resource Allocation | 2007
Gijs Hubben; Jasper M. Bos; Christa A Veltman-Starkenburg; Simon Stegmeijer; Henrik W. Finnern; B.S. Kappelhoff; Kit N. Simpson; Andrea Tramarin; Maarten Postma
131,000 and
Vox Sanguinis | 2017
Brian Custer; Mart P. Janssen; Gijs Hubben; M. Vermeulen; M. van Hulst
232,700 per additional infection averted, in high and medium prevalence settings respectively. Assuming
Transfusion | 2009
Marinus van Hulst; Gijs Hubben; Kwamena W. Sagoe; Charupon Promwong; Parichart Permpikul; Ladda Fongsatitkul; Diarmuid M. Glynn; Cees Th. Smit Sibinga; Maarten Postma
17,645 benefit per infection averted, the most cost-saving strategies in high and medium prevalence settings were selective screening with PCR and selective screening with chromogenic, respectively. Conclusions/Significance Admission screening costs
Transfusion | 2009
Marinus van Hulst; Gijs Hubben; Kwamena W. Sagoe; Charupon Promwong; Parichart Permpikul; Ladda Fongsatitkul; Diarmuid M. Glynn; Cees Th. Smit Sibinga; Maarten Postma
4,100–
Transfusion | 2009
Marinus van Hulst; Gijs Hubben; Kwamena W. Sagoe; Charupon Promwong; Parichart Permpikul; Ladda Fongsatitkul; Diarmuid M. Glynn; Cees Th. Smit Sibinga; Maarten Postma
21,200 per infection averted, depending on strategy and setting. Including financial benefits from averted infections, screening could well be cost saving.